Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Special Report
PBAC reveals giant November agenda
As anticipated, the November 2016 PBAC agenda is huge with 36 major submissions and 26 minor but comparatively few on the parallel processing track.
Approvals Action
Apotex sets sights on $146m Novartis drug
Apotex has registered two new brands for one of Novartis' biggest selling products as patent expiry looms.
PBAC Outcomes
PBAC in major denial mode
The PBAC either rejected or deferred 16 major submissions and resubmissions at its July meeting with another three parallel submissions held off because TGA data was insufficient; only seven majors were recommended for listing.
Pipeline Monitor
Gilead wins speedy review for HIV hope
Gilead has filed its latest drug combo in the US with hopes of maintaining HIV sales as hep C blockbusters fall back.